Focused Wealth Management’s Provectus Biopharmaceuticals PVCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PVCT
Focused Wealth Management's PVCT Position: Q2 2018 in Review
Focused Wealth Management sold out of Provectus Biopharmaceuticals (PVCT) in Q2 2018, closing a stake of 9,250 shares — an estimated $1K sold.
Focused Wealth Management first reported a position in PVCT in Q4 2014 and held it in 13 quarters. The position peaked at $2K in Q3 2015. 3 funds tracked by Wall St. Rank hold PVCT as of Q2 2018.
- Focused Wealth Management reported no remaining Provectus Biopharmaceuticals position as of Q2 2018 after selling out during the quarter.
- Focused Wealth Management sold 9,250 Provectus Biopharmaceuticals shares in Q2 2018, an estimated $1K.
- Focused Wealth Management first reported a position in Provectus Biopharmaceuticals in Q4 2014 and held it in 13 quarters.
- Focused Wealth Management's Provectus Biopharmaceuticals position peaked at $2K in Q3 2015.
- 3 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q2 2018.
Based on Focused Wealth Management's 13F filing for Q2 2018, filed 15 Aug 2018.